TGFB2 and familial pancreatic carcinoma: For instance, AP12009 (Trabedersen), which targets TGF-β2 mRNA, has been successfully used to treat melanomas, colon, and pancreatic cancers in a phase I study (NCT00844064) Schlingensiepen et al. demonstrated that Trabedersen decreases TGF-β2 levels in PC cells, inhibiting cell proliferation and migration.